A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

Phase 2 Completed 139 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to assess whether fracture union is accelerated in subjects with humeral fractures (proximal,diaphyseal) treated with conservative therapy (standard of care) and a single dose of rhBMP-2/CPM compared to subjects who receive standard of care alone.

Timeline

Start: 2007-01
Primary completion: 2010-02
Completion: 2010-02

Publications

Handoll HH, Elliott J, Thillemann TM, Aluko P, Brorson S. Interventions for treating proximal humeral fractures in adults. Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD000434. doi: 10.1002/14651858.CD000434.pub5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Recombinant Human Bone Morphogenetic Protein-2	Protein / enzyme biologic	1 mg/ml	—
Subject	Recombinant Human Bone Morphogenetic Protein-2	Protein / enzyme biologic	2 mg/ml	—

Indications

No indication recorded.